Pharma Investor Says $180M Deal Proxy Lacks Key Info
A shareholder of intravenous pain medication developer Avenue Therapeutics Inc. filed suit in Delaware federal court Thursday against the company's directors alleging a proxy statement describing a $180 million acquisition of...To view the full article, register now.
Already a subscriber? Click here to view full article